August 20, 2020
The Thai pharma market, one of the largest in the ASEAN region, stood at USD 5 billion in size in 2016. Thailand projects that the market will grow to USD 7 billion in 2021 and USD 9.5 billion by 2026.
Thailand’s healthcare expenditure is projected to rise from USD 24.1 billion in 2016 to USD 45.5 billion by 2026,
In general, there are no specific regulations related to the pricing of medicines.
Medicine prices are regulated only when they are one of the approximately 1500 drugs on the National List of Essential Drugs (NLED).
Under the control of the Ministry of Commerce, drugs on the NLED are subject to a median price policy. Private hospitals and drug stores are free to set their own prices for the drugs they sell, but the price must not exceed the sticker price – the maximum price set by the distributor.
Trastuzumab sample data and pricing May 2020.
August 06, 2020
Is one of your data needs and requirements the reimbursed status of medicines across Europe and other regulated and non-regulated markets?
Pharma14's coverage of reimbursed medicines status is updated on a monthly basis giving you the most up-to-date picture.
Our monthly updated platform will give you total reimbursed information for over 2,000,000 marketed medicines across 54 countries.
Sample data: Select Adalimumab prices and reimbursement status in Western European countries.
July 30, 2020
The South Korean pharmaceutical market is expanding and expected to reach more than 21 billion USD by 2021 with a compound annual growth rate (CAGR) of 2.5%, increasing from 18.6 billion USD in 2016.
The South Korean government is increasing its focus on introducing generics in order to reduce public costs.
This caused an even greater rise in the generic sector, forecasting an annual growth rate of over 7% compounded annually.
In international trade, pharmaceutical exports doubled to over 5 billion U.S. dollars in 2018. The bio-pharmaceutical sector continued to enjoy increased exports that were significantly higher than imports. Exports increased from around 400 million U.S. dollars in 2013 to almost 2 billion U.S. dollars in 2019.
Beginning this month Pharma14 has begun covering this exciting and large market in it's, monthly updated, global medicine and pricing database.
July 09, 2020
The European parallel pharmaceutical trade started in the Netherlands in the 70's and is estimated to be worth approximately € 6.5 billion (value at 2018 ex-factory prices) and between 2 - 3 % of total European medicine sales. The trade is an arbitrage between medicine prices in different countries which are negotiated between governments and the pharmaceutical industry. The medicine is sold on the same conditions as the original manufacturer’s normal packaging. All imported pharmaceuticals have to be approved by the local medical authority - or the EMA.
Share of parallel imports in pharmacy market sales as a percentage of total per country 2018
Austria - 2%
Belgium - 2%
Denmark - 27%
Germany - 9%
Ireland - 6%
Netherlands - 9%
Poland - 2%
Sweden - 14%
U.K - 10%
Pharma14 data includes all European parallel imported drugs and relevant information such as prices and reimbursement status.
Sample data: Crestor (Rosuvastatin) parallel importer in Germany. July 2020 data.
July 02, 2020
Pharmaceutical expenditure in Croatia accounted for approximately 35% of healthcare or 2.5% of GDP in 2019. Total drug expenditure in Croatia in 2019 was around $1.5 billion, which represents a 10% increase over 2018. Croatia’s pharmaceutical per capita costs are $375, the sixths highest per capita expenditure in the Central and Eastern Europe (CEE) Region.
Prescription drugs account for 90% of all pharmaceutical sales.
The Croatian pharmaceutical market is highly competitive, with market share distributed among a large group of multinational and domestic companies.
The domestic drug industry currently meets 35% of local demand in terms of value and 50% in terms of volume.
Pharma14 Sample Adalimumab, Infliximab, Vedolizumabe 2019 and 2018 consumption information:
June 25, 2020
In today’s complex clinical trial system, sourcing a drug for global trials can be challenging for even the most seasoned companies.
When it comes to sourcing, many trial sponsors are interested in single sourcing, from a single geographic source to trial sites in multiple countries.
Pharma14 is the perfect solution for allocating medicines for clinical trials whether a single or multiple sources are needed.
Pharma14 Sample: Western European Cancidas. (Caspofungin) sourcing opportunities.
Medical condition: Plasma and ELF concentrations of Caspofungin will be measured in patients requiring treatment with Cancidas (Caspofungin) for fungal infection (proven or suspected)
June 18, 2020
Dolutegravir is a WHO recommended medicine due to its low level of adverse effects and suitability for broad populations.
It is a preferred first- and second-line treatment for HIV patients.
Currently in the US market there are no generic versions of Dolutegravir.
A unique licensing agreement between ViiV and the Medicines Patent Pool (MPP) allows certain manufacturers to produce generic Dolutegravir for selected developing countries.
2020 marks the 6th year of the signing of this licensing agreement that allows generic manufacturers to produce and sell dolutegravir in countries with higher rates of HIV.
In 2020 eighteen generic manufacturers are authorized to produce and sell affordable fixed-dose or single combination versions of Dolutegravir in over 100 low-income countries.
These licensing agreements have also allowed the manufacturers to include dolutegravir in a new developed combination of tenofovir disoproxil fumarate/ lamivudine/dolutegravir.
Pharma14 Sample: Dolutegravir - Prices in selected European countries.
June 11, 2020
The health care system in Iceland is a mostly publicly funded entity. Iceland is built up of seven health care regions. The national health fund is financed from the annual budget.
The per capita public health expenditure in Iceland is slightly higher when compared to the EU average but lower as a percentage of GDP.
OECD data shows us that health spending per capita amounted to USD 3,750 in 2015 which increased to USD 4,350 in 2018.
However, Iceland spent 8.3 % of its GDP on health, less than the EU average of 9.8 % in 2017.
In Iceland, the public expenditure accounts for the bulk of health expenditure which amounts to almost 82% of current health expenditure.
Pharma14 Sample Atorvastatin 2019 and 2018 consumption information:
May 29, 2020
Pharma14 is happy to introduce the medicine and pricing information of Azerbaijan.
The pharmaceutical market of Azerbaijan is the largest in Transcaucasia despite the fact that the local pharmaceutical industry is quite undeveloped.
After independence, the state wholesale companies were privatized. Local medicine manufacturing is limited with over 90% of the market being imported.
Parallel import is allowed in the country.
Current pharmaceutical market size is approximately 1 billion USD with a high growth rate nearing 10%.
Trastuzumab sample data and pricing.
Atorvastatin sample data and pricing.
May 14, 2020
Consumption and sales data of Hungary are now available on Pharma14.
This data covers 2019 and 2018 information, spanning close to 5000 Rx and OTC molecules in the hospital and pharmacy channels.
Pharma14 Sample Atorvastatine:
Pharma14 Sample Denosumab:
April 29, 2020
As doctors and other health officials around the world race to find treatments and a possible cure for the novel Coronavirus, two drugs have jumped to the front of the conversation: chloroquine and hydroxychloroquine.
Recent news is indicating that the state of New York moved to begin trials Tuesday, procuring 70,000 doses of hydroxychloroquine and 750,000 doses of chloroquine.
Furthermore, the drug maker Bayer, has donated approximately 3 million doses of Resochin, its brand name for chloroquine, to the US federal government.
With Pharma14's global medicine and pricing database you can track and locate all Marketing Authorizations and manufacturers of these two important molecules globally.
Pharma14 Sample Chloroquine Germany data:
April 14, 2020
India is a major and fast-growing player in the pharmaceutical market.
Being the world’s largest provider of generic drugs, it accounts for over 20% of the global production by volume. India also supplies over 50% of the world’s vaccine output.
Overall production in India accounts for 10% of the global medicine supply by volume and close to 2% by value. India is the source of 3,000 pharmaceutical companies and 60,000 generic brands across 60 therapeutic categories, manufacturing more than 500 different Active Pharmaceutical Ingredients (APIs).
The local pharmaceutical market is expected to reach US$ 21 billion by the end of 2020 with high single digit growth.
Propofol sample data and pricing.
March 29, 2020
Vietnam’s pharmaceutical market grew rapidly in the last ten years. Despite some bureaucratic restrictions Vietnam offers great opportunity for suppliers looking to break into this market of close to 100 million people.
In 2018 Vietnam’s healthcare market’s value reached an estimated USD18 billion, with a per-capita expenditure that is expected to double in the next few years.
Vietnam’s pharmaceutical market turnover in 2019 was well above USD6 billion making it the second largest in South East Asia.
Local drug manufacturers are currently meeting about half of the market demand with imports filling in the second 50%.
Pharma14 is happy to announce Vietnam medicine data and tender pricing as the latest additions to our platform.
Sample Vietnam data: Trastuzumab. Ex-factory tender pricing.
March 15, 2020
We are sorry to have missed you at the euroPLX in Berlin that was supposed to have taken place this week.
Due to the current health environment the conference was canceled.
As an alternative we would like to offer you a live demonstration.
Pharma14 is the ideal platform for locating customers, suppliers and potential partners from the comfort of your desk.
• 47 full country medicine database.
• 2,000,000 medicines (Rx and OTC) - full information about each drug including - Ex-factory, Wholesale and retail prices + reimbursed information.
• First approval date and marketing authorizations for all molecules from USA, Europe.
• Monthly updates!
• Full European parallel import information.
• Excel downloads.
• Active ingredients, ATC code classification, administration routes, strength, trade names, MA holder information, real manufacturer information, PIL's and more.
• Consumption and sales data for USA, Germany, UK, France, Italy, Scandinavia, Baltic countries, Canada and more.
• "Market Opportunity Locator". Find the molecules with the least competition per country!
• Track first generic registrations of patented medicines as they happen.
• Most competitive and affordable yearly membership costs.
As always we would be happy to set up a live demonstration of Pharma14.
Direct tel: +188.8.131.5200
March 15, 2020
The Taiwan Ministry of Health reported that Taiwan’s population will increase till 2021, along with an increase in the population of seniors. As a result, national health expenditure will continue to increase. In 2017 , Taiwan’s national health expenditure amounted to US $37.5 billion, which is 6.4% of gross domestic product (GDP), which represents an increase of 3.7% over the previous year. About 60.8% of Taiwan’s healthcare expenditures are funded by the public sector, with the remaining 39.6% covered by the private sector.
Pharma14 covers over 40,000 registered medicines in Taiwan including ex-factory tender pricing information.
Sample Taiwan data: Trastuzumab. Ex-factory tender pricing.
December 15, 2019
The Philippines is considered the 10th most attractive pharmaceutical market in the Asia-Pacific region and the third-largest in the ASEAN group.
The country’s pharmaceutical industry is projected to grow by 4.5 per cent annually over the next five years reaching over PHP 209 billion in 2020 from PHP167 billion in 2014.
Government budget for health is significantly increasing:
29% growth from US$1.57 billion in 2014 to US$2.02 billion in 2018
The growing population and economic development in the Philippines point to a pharmaceutical market of 110 million population.
Healthcare spending vs GDP is growing from 2.79% in 2002 to 4.7% in 2017 (US$12.6 billion).
Pharma14 brings you national tender information information as well as wide coverage on ex-factory, wholesale and retail pricing.
Sample Philippines data: Trastuzumab. Ex-factory tender pricing.
September 29, 2019
Pharma14 database tracks and presents medicine historical pricing from 45 countries.
This tool gives Pharma14 members a quick and easy to use tool to check trends and forecast movement going forward.
Tracking the prices of expiring patented molecules as well as niche medicines are a few of the benefits historical pricing data can give a pharmaceutical professional.
Sample data: Avodart / Dutasteride historical pricing in Greece. 0.5 mg tablets. 30 per pack.
September 15, 2019
China’s pharmaceutical sector is currently being transformed into a high-quality and innovative-focused industry, reflected by the growth of new drug and clinical trial approvals in recent years.
This is being driven by factors such as a rapidly aging society, higher healthcare demands, drug regulation reforms, and increased investment inflows.
Healthcare is one of the most exciting sectors in China, growing above 10 percent annually with 2018 pharmaceutical imports approaching $15 billion.
Pharma14's monthly updated platform tracks the pharmaceutical landscape and pricing environment of the Chinese market.
September 08, 2019
August 28, 2019
August 21, 2019
August 14, 2019
July 31, 2019
July 23, 2019
July 09, 2019
June 25, 2019
There are quite a few ways to move through a medigcine database but one of the most powerful and useful is an accurate and updated ATC code search.
The Anatomical Therapeutic Chemical (ATC) Classification is an internationally accepted classification system for medicines based on therapeutic indication.
While doing due diligence pertaining to a certain molecule, one of the most important steps besides looking at competitors is the close examination of other molecules that may be competing for the same patients.
ATC search ability can give Institutional and HMO buyers an advantage while negotiating with suppliers as the full alternative medicine landscape will be available to them.
ATC 4 search is standard feature available to all members of the Pharma14 platform.
ATC4 level C08CA (Dihydropyridine Derivatives ) in UK:
June 18, 2019
Russia medicine manufacturer data is now available on Pharma14.
This data will be complementary to all other data such as MA holder, ex-factory, wholesale and retail pricing, consumption and more.
Sample data: Adalimumab.
June 11, 2019
USA medicine manufacturer data is now available on Pharma14.
This data will be complementary to all other data such as MA holder, ex-factory, wholesale and retail pricing, consumption and more.
Sample data: Paricalcitol Injections.
June 04, 2019
May 28, 2019
Pharma14 has been tracking the Russian pharmaceutical market closely and can confirm reports that the number of medicines in the nationally important VED list has increased.
The vital and essential medicine list in Russia includes those drugs that are price regulated and reimbursed, giving equal access.
The overall number of medicines in the vital and essential list has increased approximately by 500 over the last year. This would include various concentrations and pack sizes.
Lately the Russian government has added 35 new molecules to the VED list including Lapatinib and Elsulfavirine.
Furthermore the prices of medicines on the VED list will remain unchanged.
On the manufacturing side, it is reported that 80% of all VED medicines are now manufactured locally.
Sample data: Lapatinib (Tayverb) and Elsulfavirine (Elpida).
May 21, 2019
The EU recently adopted new measures to increase the competitive strength of its generic and biosimilar manufacturers. Regulation (EC) No 469/2009.
This new legislation will grant exceptions to the protection of original medicines (SPC - Supplementary protection certificate) in the case of export or stockpiling for EU 'day-one' entry.
Due to this new rule, EU manufacturers will be allowed to produce generic medicines or a biosimilar versions of a SPC protected medicine while the SPC is still in force, if the purpose of this manufacturing is for export to a non EU country where protection has already expired or never existed previously.
In the case of EU stockpiling, the new measure grants producers the right to start manufacturing during the six month period before SPC expiration.
This new measure will ensure rapid entry into market of generics and biosimilars on expiration day.
May 14, 2019
The HIV medicine market size was valued at US$28 billion in 2018 and has grown at close to 10% since 2014.
With key brand patent expiration's coming in the next 5 years market growth is expected to slow down. A lower CAGR is expected for HIV drugs until 2026 where after growth is expected to become negative.
Growing at 14% for the last 5 years the North American markets accounted for 65% of the overall HIV drug market in 2016. The North American market is expected to continue growing at a lower CAGR of 0.45% for the next 10 years but still account for close to 70% of the total global market.
Pharma14 global medicine index continuously tracks all HIV medicine prices and consumption with standard monthly updates.
Top selling HIV medicines. Germany snapshot. . Atripla, Isentress, Prezista, Stribild, Tivicay, Triumeq, Truvada, Viread.
May 07, 2019
Pharma14 is glad to announce the addition of the United Arab Emirates to its global medicine database.
The United Arab Emirates pharmaceutical market, is currently valued at $2.7 billion.
This figure represents 16.3% of the national healthcare budget.
Patented pharmaceutical spending represents 67.2% of total medicines sold while generics and OTC products are standing at 18.4% and 14.4% respectively.
Rx medicines account for 85.6% of the total pharmaceutical market.
The U.A.E. healthcare market is quickly growing. In 2017, healthcare expenditures in the U.A.E. reached $17 billion and are expected to rise to $21.3 billion by 2021.
Overall healthcare spending is projected to account for 4.6% of a country’s GDP by 2026 from 4.2% in 2016
April 30, 2019
For many companies in the pharmaceutical chain knowing who is the manufacturer of a medicine has an important advantage with many practical uses including business development decisions.
Today's market unique database provider who carries such information is Pharma14.
A few of the advantages of having actual manufacturer information may include:
1. Find CMO's with specific hard to find manufacturing capabilities.
2. Use Pharma14 filtering tools to cross reference manufacturers with administration routes and dosage forms.
3. Cross reference manufacturers vs. MA holders or active ingredients.
4. Map out the connecting parent manufacturer with a specific medicine across multiple countries and regions.
5. Locate manufacturers for direct licensing agreements.
6. Help pharmaceutical companies, API producers and others to seek out partner FDF manufacturers.
Sample data: Spain Dutasteride manufacturers. 0.5 mg capsules.
April 24, 2019
Consumption and sales data of UK prescription medicines for 2018 is now available on Pharma14.
This includes pharmacy and hospital channels for England, Scotland, Wales and N. Ireland.
In overall numbers, the cost of prescriptions dispensed in 2018 was USD 13.54 billion . A small but significant decrease of 3.7% from USD 14.07 billion in 2017
In 2018 as well as in 2017 roughly 1.3 billion medicines were prescribed in the UK with a slight increase of 0.3% from 2017 to 2018.
Sample data: Enoxaparin 100 mg and 150 mg injection consumption and sales.
2017 vs. 2018 data including consumption and sales movement.
Note: Generic Arovi came onto the market in 2018. (Line 8).
April 17, 2019
The orphan drugs market is growing annually at roughly 7%. Total orphan drug sales will rise from $127bn for 2017 to $217bn in 2022.
An orphan drug can be defined as an agent specifically designed to treat rare (orphaned) diseases.
Prior to 1983 R&D of orphan drugs was limited but a US orphan drug act at that time gave incentive to the new development of these medicines.
NORD (The National Organization for Rare Disorders), one of the backers of the original act estimates 30 million Americans suffer from thousands of rare diseases.
The 1983 act paved way for other countries to follow suite, notably the European Union in 2000 and Japan a decade earlier.
The Pharma14, monthly updated, platform tracks and lists all marketing authorizations, including orphan drugs across 41 countries.
Sample data: Orphan drug Nitisinone in German market. 2 mg, 5 mg, 10 mg, 20 mg capsules.
April 02, 2019
March 26, 2019
March 19, 2019
March 12, 2019
March 05, 2019
February 26, 2019
February 19, 2019
February 12, 2019
February 05, 2019
January 29, 2019
January 22, 2019
January 15, 2019
January 08, 2019
January 01, 2019
60 Medinat Hayehudim St.
Entrance C. Third floor.